Silvercrest Asset Management Group LLC Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Silvercrest Asset Management Group LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,630 shares of the medical research company’s stock after buying an additional 1,053 shares during the period. Silvercrest Asset Management Group LLC’s holdings in Thermo Fisher Scientific were worth $26,521,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of TMO. LifeSteps Financial Inc. purchased a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $31,000. Northwest Financial Advisors purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. True Wealth Design LLC grew its position in Thermo Fisher Scientific by 1,275.0% in the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 51 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth about $32,000. Finally, Pineridge Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $1,201,700.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,860,920.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,860,920.55. The disclosure for this sale can be found here. Insiders sold 16,784 shares of company stock worth $9,801,825 over the last 90 days. 0.34% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft upped their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. TD Cowen boosted their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Robert W. Baird raised their target price on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Raymond James increased their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

Thermo Fisher Scientific Stock Performance

TMO traded up $3.51 during trading on Tuesday, hitting $607.63. 599,583 shares of the stock were exchanged, compared to its average volume of 1,558,115. The firm has a market capitalization of $231.94 billion, a P/E ratio of 39.13, a PEG ratio of 2.83 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $614.79. The stock has a fifty day moving average price of $563.21 and a two-hundred day moving average price of $566.38. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.15 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.